ASCENTAGE-B：ANNOUNCEMENTOFANNUALRESULTSFORTHEYEARENDEDDECEMBER312025;ANDCHANGEOFCOMPANYSECRETARYANDAUTHORISEDREPRESENTATIVE.pdf

1、1Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in relia

2、nce upon the whole or any part of the contents of this announcement.ASCENTAGE PHARMA GROUP INTERNATIONAL亞 盛 醫 藥 集 團(Incorporated in the Cayman Islands with limited liability)(Stock Code:6855)ANNOUNCEMENT OF ANNUAL RESULTS FORTHE YEAR ENDED DECEMBER 31,2025;ANDCHANGE OF COMPANY SECRETARY AND AUTHORIS

3、ED REPRESENTATIVE Product sales and commercial rights revenue in 2025 increased 90%year-over-year to RMB574.1 million(US$82.1 million)Sales of Olverembatinib in 2025 increased 81%year-over-year to RMB435.3 million(US$62.2 million)Sales of Lisaftoclax since launch during last five months of 2025 were

4、 RMB70.6 million(US$10.1 million)Nine registrational phase III clinical trials in progress worldwide,including four cleared by FDA and EMAAscentage Pharma Group International(referred hereinto as“Ascentage Pharma,”the“Company,”the“Group,”“we,”“us”or“our”),a global,commercial stage,integrated biophar

5、maceutical company engaged in the discovery,development and commercialization of novel,differentiated therapies to address unmet medical needs in cancer,is pleased to announce its unaudited financial results for the year ended December 31,2025,and updates on key clinical and commercial developments.

6、Dr.Dajun Yang,Chairman and Chief Executive Officer of Ascentage Pharma,said,“As we reflect on our achievements in 2025,I am delighted to report that Ascentage Pharma has made remarkable strides in advancing our mission to deliver innovative therapies to patients worldwide.On January 28,2025,the Comp